Download PDF
psychoneuro 2003; 29(9): 409-414
DOI: 10.1055/s-2003-43144
Schwerpunkt

© Georg Thieme Verlag Stuttgart · New York

Quetiapin in der Behandlung der bipolaren affektiven Störung

Quetiapine in the treatment of bipolar disorderStephanie Krüger1 , Werner Felber2 , Peter Bräunig3
  • 1Center for Addiction and Mental Health, Clarke Institute of Psychiatry, Mood and Anxiety Disorders Division and PET Center, Toronto, Canada
  • 2Klinik für Psychiatrie und Psychotherapie des Universitätsklinikums Carl-Gustav Carus, Dresden
  • 3Klinik für Psychiatrie, Verhaltensmedizin und Psychosomatik am Klinikum Chemnitz, Akademisches Lehrkrankenhaus der Universität Dresden
Further Information

Publication History

Publication Date:
24 October 2003 (online)

   Permissions and Reprints

Zusammenfassung

Quetiapin ist ein atypisches Neuroleptikum, das sowohl Positiv- als auch Negativsymptome schizophrener Erkrankungen günstig beeinflusst, ohne extrapyramidalmotorische Nebenwirkungen auszulösen oder die Kognition ungünstig zu beeinflussen. Es gibt mittlerweile vier Fallberichte, sieben offene Studien, eine plazebokontrollierte, randomisierte Studie und eine retrospektive Untersuchung zum Einsatz von Quetiapin bei akuten Manien und therapierefraktären bipolaren Erkrankungen bei verschiedenen Patientengruppen. Insgesamt scheint Quetiapin stimmungsstabilisierende Eigenschaften bei einem günstigen Verträglichkeitsprofil zu haben. Doppelblinde, plazebokontrollierte Studien müssen jedoch durchgeführt werden, um verbindliche Aussagen zum Einsatz von Quetiapin bei bipolaren Erkrankungen machen zu können.

Summary

Quetiapine is a novel antipsychotic, which is efficacious in the treatment of positive and negative symptoms in schizophrenia. It does neither worsen cognitive symptoms nor does it exacerbate extrapyramidal motor symptoms. There are 4 case reports, 7 open studies, 1 placebo controlled randomized and 1 retrospective study investigating its use in the treatment of bipolar disorder. Quetiapine seems to have mood stabilizing properties and a good safety profile. Double-blind placebo controlled studies are warranted to confirm these preliminary findings.

Literatur

  • 1 Coryell W, Leon AC, Turvey C, Akiskal HS, Mueller T, Endicott J. The significance of psychotic features in manic episodes: a report from the NIMH collaborative study.  J Affect Disord. 2001;  67 79-88
    CrossrefPubMedGoogle Scholar
  • 2 Fennig S, Bromet EJ, Karant MT, Ram R, Jandorf L. Mood-congruent versus mood-incongruent psychotic symptoms in first-admission patients with affective disorder.  J Affect Disord. 1996;  37 23-29
    CrossrefPubMedGoogle Scholar
  • 3 Goodwin K. F., Jamison KR. Manic-depressive illness.  New-York: Oxford University Press. 1990; 
    PubMedGoogle Scholar
  • 4 Swann AC, Janicak PL, Calabrese JR, Bowden CL, Dilsaver SC, Morris DD. et al. . Structure of mania: depressive, irritable, and psychotic clusters with different retrospectively-assessed course patterns of illness in randomized clinical trial participants.  J Affect Disord. 2001;  67 123-132
    CrossrefPubMedGoogle Scholar
  • 5 Greil W, Kleindienst N, Erazo N, Muller-Oerlinghausen B. Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder.  J Clin Psychopharmacol. 1998;  18 455-460
    CrossrefPubMedGoogle Scholar
  • 6 Tohen M, Hennen J, Zarate CM, Jr., Baldessarini RJ, Strakowski SM, Stoll AL. et al. . Two-year syndromal and functional recovery in 219 cases of first-episode major affective disorder with psychotic features.  Am J Psychiatry. 2000;  157 220-228
    CrossrefPubMedGoogle Scholar
  • 7 Maj M, Pirozzi R, Bartoli L, Magliano L. Long-term outcome of lithium prophylaxis in bipolar disorder with mood-incongruent psychotic features: a prospective study.  J Affect Disord. 2002;  71 195-198
    CrossrefPubMedGoogle Scholar
  • 8 Weizman R, Weizman A. Use of atypical antipsychotics in mood disorders.  Curr Opin Investig Drugs. 2001;  2 940-945
    PubMedGoogle Scholar
  • 9 Lakshmi N, Yatham MBBS. The role of novel antipsychotics in bipolar disorder.  J Clin Psychiatry. 2002;  63 10-14
    PubMedGoogle Scholar
  • 10 Tohen M, Zarate CAJr. Antipsychotic agents in bipolar disorder.  J Clin Psychiatry. 1998;  59 38-48
    PubMedGoogle Scholar
  • 11 Brotman MA, Fergus EL, Post RM, Leverich GS. High exposure to neuroleptics in bipolar patients: a retrospective review.  J Clin Psychiatry. 2000;  61 68-72
    PubMedGoogle Scholar
  • 12 Nasrallah HA, Churchill CM, Hamdan-Alla GA. Higher frequency of neuroleptic-induced dystonia in mania than in schizophrenia.  Am J Psychiatry. 1998;  145 1455-1456
    PubMedGoogle Scholar
  • 13 Mukherjee S, Rosen AM, Caracci G, Shukla S. Persistent tardive dyskinesia in bipolar patients.  Arch Gen Psychiatry. 1986;  43 342-346
    PubMedGoogle Scholar
  • 14 Calabrese JR, Kimmel SE, Woyshville MJ. Clozapine for the treatment of refractory mania.  Am J Psychiatry. 1996;  153 759-764
    CrossrefPubMedGoogle Scholar
  • 15 Segal J, Berk M, Brook S. Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial.  Clin Neuropharmacol. 1998;  21 176-180
    PubMedGoogle Scholar
  • 16 Sachs GS. Safety and efficacy of risperidone versus placebo in combination with lithium or valproate in the treatment of the manic phase of the bipolar disorder.  In J Neuropsychopharmacol. 2000;  3 143; 
    PubMedGoogle Scholar
  • 17 Kopala LC, Good KP, Honer WG. Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low-dose risperidone.  J Clin Psychopharmacol. 1997;  17 308-313
    CrossrefPubMedGoogle Scholar
  • 18 Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol.  Risperidone Study Group Br J Psychiatry. 1995;  166 712-726
    CrossrefPubMedGoogle Scholar
  • 19 Malhotra S, McElroy SL. Medical management of obesity associated with mental disorders.  J Clin Psychiatry. 2002;  63 24-32
    PubMedGoogle Scholar
  • 20 Tohen M, Sanger TM, McElroy SL. Olanzapine versus placebo in the treatment of acute mania.  Am J Psychiatry. 1999;  156 702-709
    PubMedGoogle Scholar
  • 21 Tohen M, Jacobs TG, Grundy SL. The olanzapine HGGW Study Group. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study.  Arch Gen Psychiatry. 2000;  57 841-849
    CrossrefPubMedGoogle Scholar
  • 22 Sanger TM, Grundy SL, Gibson PJ. Long-term olanzapine therapy in the treatment of bipolar-I disorder: an open-label continuation-phase study.  J Clin Psychiatry. 2001;  62 273-281
    PubMedGoogle Scholar
  • 23 Berk, Ichim L, Brook S. Olanzapine compared to lithium in mania.: a double-blind randomized controlled trial.  Int Clin Psychopharmacol. 1999;  14 339-343
    CrossrefPubMedGoogle Scholar
  • 24 McIntyre RS. Psychotropic drugs and adverse events in the treatment of bipolar disorders revisited.  J Clin Psychiatry. 2002;  63 3;  15-20
    PubMedGoogle Scholar
  • 25 Arvanitis LA, Miller BG. Multiple fixed doses of seroquel in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo.  Biol Psychiatry. 1997;  42 233-246
    CrossrefPubMedGoogle Scholar
  • 26 Small JG, Hirsch SR, Arvanitis LA. Quetiapine in patients with schizophrenia: a high and low dose double-blind comparison with placebo.  Arch Gen Psychiatry. 1997;  54 549-557
    CrossrefPubMedGoogle Scholar
  • 27 Sajatovic M, Brescan DW, perez DE, DiGiovanni SK, Hattab H., Ray JB, Bingham CR. Quetiapine anlone and added to a mood stabilizer for serious mood disorders.  J Clin Psychiatry. 2001;  62 728-732
    PubMedGoogle Scholar
  • 28 Dunayevich E, Tugrul RN, Strakowski SM. Quetiapine in the treatment of mania.  International Congress on Schizophrenia Research, Whistler. 2001; 
    PubMedGoogle Scholar
  • 29 Dunayevich E, Strakowski SM. Quetiapine for treatment-resistant mania.  Am J Psychiatry. 2000;  157 1341
    CrossrefPubMedGoogle Scholar
  • 30 Altamura C, Madaro D, Salvadori D. Quetiapine in acute mania: a case report (with a six-month follow-up).  Int J Psychiatry Clin Pract. 2001;  5 283-285
    PubMedGoogle Scholar
  • 31 Zarate CA, Rothshild A, Fletcher KE, Madrid A, Zapatel J. Clinical predictors of acute response with quetiapine in psychotic mood disorders.  J Clin Psychiatry. 2000;  61 185-189
    PubMedGoogle Scholar
  • 32 Madhusoodanan S, Brenner R, Alcantra A. Clinical experience with quetiapine in the elderly with psychotic diosrders.  J Geriatr Psychiatr Neurol. 2000;  13 18-32
    PubMedGoogle Scholar
  • 33 Chisholm K, Dennehy E, Suppes T. Clinical response to quetiapine add-on for treatment of refractory bipolar disorder.  Fourth International Conference on bipolar disorder, Pittsburgh, June. 2001; 
    PubMedGoogle Scholar
  • 34 Ghaemi SN, Katzow JJ. The use of quetiapine for treatment-resistant bipolar disorder: a case series.  Ann Clin Psychiatry. 2000;  11 137-140
    PubMedGoogle Scholar
  • 35 Schaller JL, Behar D. Quetiapine for refractory mania in a child.  J Am Acad Child Adolesc Psychiatry. 1999;  38 498-499
    PubMedGoogle Scholar
  • 36 Alston JF. Remission of treatment-resistant bipolar disorder I with quetiapine in an adolescent.  7th World Congress of Biological Psychiatry, July. 2001; 
    PubMedGoogle Scholar
  • 37 DelBello MP, Schwiers ML, Rosenberg HL, Seshadri V, Wilhoit SR, Strakowski SM. Quetiapine as adjunctive treatment to adolescent mania.  Fourth International Conference on bipolar disorder, Pittsburgh, June. 2001; 
    PubMedGoogle Scholar
  • 38 Ghaemi SN, Goldberg JF, Koo JY, McNally EE. Quetiapine treatment of rapid cycling bipolar disorder: an open prospective study.  Fourth International Conference on Bipolar Disorder, Pittsburgh, June. 2001; 
    PubMedGoogle Scholar
  • 39 Brown ES, Nejtek VA, Perantie DC, Bobadilla L. Quetiapine in patients with bipolar disorder and cocaine dependence.  4th International Conference on Bipolar Disorder, Pittsburgh, June. 2001; 
    PubMedGoogle Scholar

Korrespondenzadresse

PD. Dr. med. Stephanie Krüger

Center for Addiction and Mental Health, Clarke Institute of Psychiatry

Mood and Anxiety Disorders Division and PET Center, University of Toronto, Canada

Email: Stephanie_Krueger@camh.net